Please wait while the formulary information is being retrieved.
ARZERRA (OFATUMUMAB)
- Chronic lymphocytic leukemia
- Progressive chronic lymphocytic leukemia
- Relapsed chronic lymphocytic leukemia
1,000 mg/50 mL intravenous solution
- Dosage information is not available
100 mg/5 mL intravenous solution
- Dosage information is not available
Chronic lymphocytic leukemia
- Infuse 1,000 mg by intravenous route on day 1 of a 28 day cycle (maximum infusion rate 400 ml/hr)
Progressive chronic lymphocytic leukemia
- Inject 2,000 mg by intravenous route once weekly for 7 doses (doses 2Through 8)
- Inject 2,000 mg by intravenous route every 4 weeks for 4 doses (doses9 through 12)
- Infuse 1,000 mg by intravenous route every 8 weeks (maximum infusion rate 400 ml/hr)
- Infuse 1,000 mg by intravenous route every 8 weeks for up to 2 years (maximum infusion rate 400 ml/hr)
Relapsed chronic lymphocytic leukemia
- Infuse 1,000 mg by intravenous route on day 1 of a 28 day cycle (maximum infusion rate 400 ml/hr)
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
- Progressive multifocal leukoencephalopathy
- Reactivation of hepatitis B
Contraindicated
- Angina
- Chronic obstructive pulmonary disease
- Hepatitis B immune due to latent hepatitis B infection
- Pregnancy
- Severe infection
Severe
Moderate
- Anemia
- Neutropenic disorder
- Thrombocytopenic disorder
ARZERRA (OFATUMUMAB)
- Chronic lymphocytic leukemia
- Progressive chronic lymphocytic leukemia
- Relapsed chronic lymphocytic leukemia
- Anemia
- Cytokine release syndrome
- Dyspnea
- Fever
- Lymphopenia
- Neutropenic disorder
- Pneumonia
- Thrombocytopenic disorder
- Bronchitis
- Cough
- Diarrhea
- Fatigue
- Nausea
- Skin rash
- Upper respiratory infection
More Frequent
Severe
Less Severe
- Bacterial infection
- Bacterial sepsis
- Chemotherapy-induced hyperuricemia
- Chills
- Fungal infection
- Headache disorder
- Herpes simplex infection
- Herpes zoster
- Hypertension
- Hypotension
- Infection
- Leukopenia
- Tachycardia
- Urticaria
- Viral infection
- Arthralgias
- Back pain
- General weakness
- Hyperhidrosis
- Insomnia
- Muscle spasm
- Peripheral edema
- Sinusitis
- Upper abdominal pain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Anaphylaxis
- Angioedema
- Bronchospastic pulmonary disease
- Cardiac arrest
- Gastrointestinal obstruction
- Hepatic failure
- Hypersensitivity drug reaction
- Laryngeal edema
- Porphyria cutanea tarda
- Progressive multifocal leukoencephalopathy
- Pulmonary edema
- Reactivation of hepatitis B
- Stevens-johnson syndrome
- Viral hepatitis B
Less Severe
- Flushing
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Ofatumumab
Safety and efficacy not established in pediatrics.
- 1 Day – 18 Years
- Safety and efficacy not established in pediatrics.
Ofatumumab
- Severity Level:
D
- Additional Notes: Animal data show peripheral b cell depletion in fetus & decr spleen/placenta wt
Contraindicated
Ofatumumab
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Insufficient human data available |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This drug may cause serious (possibly fatal) liver disease. Also, if you have a current or past infection with hepatitis B, this drug may cause the infection to return or worsen. This may occur during treatment or after treatment is finished.<br /><br />Before starting treatment with this medication, your doctor may order a test to see if you have hepatitis B infection. Your doctor may also order blood tests and watch for symptoms of liver disease during treatment and for months after your last dose of this medication. Get medical help right away if you have any symptoms of liver damage, including: persistent nausea/vomiting, loss of appetite, stomach/abdominal pain, yellowing eyes/skin, dark urine.<br /><br /> Ofatumumab increases your risk of getting a rare but very serious (sometimes fatal) brain infection (progressive multifocal leukoencephalopathy-PML). Get medical help right away if you develop any signs of PML, including: loss of balance/dizziness, confusion, difficulty walking/talking, seizure, vision changes.
| Chronic lymphocytic leukemia | |
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| Progressive chronic lymphocytic leukemia | |
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| Relapsed chronic lymphocytic leukemia | |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| 0-9 | A-Z |
|---|---|
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.1 | Chronic lymphocytic leukemia of b-cell type |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.10 | Chronic lymphocytic leukemia of b-cell type not having achieved remission |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
| C91.12 | Chronic lymphocytic leukemia of b-cell type in relapse |
Formulary Reference Tool